Intravacc expands analytical services

Intravacc, a leading global contract development and manufacturing organization, has announced an expanded commercial focus on integrated analytical services for vaccine and biologics developers. These services aim to support partners from product characterization and assay development to GMP readiness and clinical manufacturing. Intravacc offers state-of-the-art analytical methods for identity, content, purity, structure, formulation, stability, and preclinical assessment, including LC-MS, HPLC, biosensor analysis, qPCR, ELISA, biochemical, biophysical, immunological, and cell-based assays. This integrated approach is designed to help partners define quality attributes, reduce CMC risk, and accelerate vaccine candidates toward clinical studies, ultimately streamlining the path from early-stage research to Phase I/II clinical production.